Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3467-3477

  Poplawski, Sarah E ^a,b   Lai, Jack H ^a,b   Li, Youhua ^a   Jin, Zhiping ^a   Liu, Yuxin ^a   Wu, Wengen ^a   Wu, Yong ^a   Zhou, Yuhong ^a   Sudmeier, James L ^a   Sanford, David G ^a,b   Bachovchin, William W ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b Arisaph Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARI 3099; ARI 3531; BORONIC ACID DERIVATIVE; BORTEZOMIB; N (PYRIDINE 4 CARBONYL)DEXTRO ALANYLBOROPROLINE; N (PYRIDINE 4 CARBONYL)DEXTROVALYLBOROPROLINE; SEPRASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTROPHILICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; SUBSTITUTION REACTION;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BORONIC ACIDS; DRUG DISCOVERY; GELATINASES; HEK293 CELLS; HUMANS; MEMBRANE PROTEINS; MICE; PROLINE; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 84877690891     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400351a     Document Type: Article

References (42)

1. Garin-Chesa, P.; Old, L. J.; Rettig, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7235-7239
2. Rettig, W. J.; Garin-Chesa, P.; Healey, J. H.; Su, S. L.; Ozer, H. L.; Schwab, M.; Albino, A. P.; Old, L. J. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin Cancer Res. 1993, 53, 3327-3335
3. Rettig, W. J.; Su, S. L.; Fortunato, S. R.; Scanlan, M. J.; Raj, B. K.; Garin-Chesa, P.; Healey, J. H.; Old, L. J. Fibroblast activation protein: purification, epitope mapping and induction by growth factors Int. J. Cancer 1994, 58, 385-392
4. Park, J. E.; Lenter, M. C.; Zimmermann, R. N.; Garin-Chesa, P.; Old, L. J.; Rettig, W. J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts J. Biol. Chem. 1999, 274, 36505-36512
5. Connolly, B. A.; Sanford, D. G.; Chiluwal, A. K.; Healey, S. E.; Peters, D. E.; Dimare, M. T.; Wu, W.; Liu, Y.; Maw, H.; Zhou, Y.; Li, Y.; Jin, Z.; Sudmeier, J. L.; Lai, J. H.; Bachovchin, W. W. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety J. Med. Chem. 2008, 51, 6005-6013
6. Maes, M.; Lambeir, A.; Gilany, K.; Senten, K.; Van der Veken, P.; Leiting, B.; Augustyns, K.; Scharpé, S.; De Meester, I. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivitives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7) Biochem. J. 2005, 386, 315-324
7. Yoshimoto, T.; Fischl, M.; Orlowski, R. C.; Walter, R. Post-proline cleaving enzyme and post-proline dipeptidyl aminopeptidase. Comparison of two peptidases with high specificity for proline residues J. Biol. Chem. 1978, 253, 3708-3716
8. Levy, M. T.; McCaughan, G. W.; Abbott, C. A.; Park, J. E.; Cunningham, A. M.; Muller, E.; Rettig, W. J.; Gorrell, M. D. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodeling interface in human cirrhosis Hepatology 1999, 29, 1768-1778
9. Vanhoof, G.; Goossens, F.; De Meester, I.; Hendriks, D.; Scharpé, S. Proline motifs in peptides and their biological processing FASEB J. 1995, 9, 736-744
10. Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum Eur. J. Biochem. 1993, 214, 829-835
11. Kieffer, T. J.; McIntosh, C. H.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 1995, 136, 3585-3596
12. Choy, M.; Lam, S. Sitagliptin: a novel drug for the treatment of type 2 diabetes Cardiol. Rev. 2007, 15, 264-271
13. Cheng, J. D.; Dunbrack, R. L., Jr.; Valianou, M.; Rogatko, A.; Alpaugh, R. K.; Weiner, L. M. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model Cancer Res. 2002, 62, 4767-4772
14. Scott, A. M.; Wiseman, G.; Welt, S.; Adjei, A.; Lee, F. T.; Hopkins, W.; Divgi, C. R.; Hanson, L. H.; Mitchell, P.; Gansen, D. N.; Larson, S. M.; Ingle, J. N.; Hoffman, E. W.; Tanswell, P.; Ritter, G.; Cohen, L. S.; Bette, P.; Arvay, L.; Amelsberg, A.; Vlock, D.; Rettig, W. J.; Old, L. J. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer Clin. Cancer Res. 2003, 9, 1639-1647
15. Puré, E. The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer Expert Opin. Ther. Targets 2009, 13, 967-973
16. Santos, A. M.; Jung, J.; Aziz, N.; Kissil, J. L.; Puré, E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice J. Clin. Invest. 2009, 119, 3613-3625
17. Cheng, J. D.; Valianou, M.; Canutescu, A. A.; Jaffe, E. K.; Lee, H. O.; Wang, H.; Lai, J. H.; Bachovchin, W. W.; Weiner, L. M. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth Mol. Cancer Ther. 2005, 4, 351-360
18. Kraman, M.; Bambrough, P. J.; Arnold, J. N.; Roberts, E. W.; Magiera, L.; Jones, J. O.; Gopinathan, A.; Tuveson, D. A.; Fearon, D. T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha Science 2010, 330, 827-830
19. Huang, Y.; Simms, A. E.; Mazur, A.; Wang, S.; León, N. R.; Jones, B.; Aziz, N.; Kelly, T. Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions Clin. Exp. Metastasis 2011, 28, 567-579
20. Adams, S.; Miller, G. T.; Jesson, M. I.; Watanabe, T.; Jones, B.; Wallner, B. P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism Cancer Res. 2004, 64, 5471-5480
21. Edosada, C. Y.; Quan, C.; Wiesmann, C.; Tran, T.; Sutherlin, D.; Reynolds, M.; Elliott, J. M.; Raab, H.; Fairbrother, W.; Wolf, B. B. Selective inhibition of fibroblast activation protein based on dipeptide substrate specificity J. Biol. Chem. 2006, 281, 7437-7444
22. Tran, T.; Quan, C.; Edosada, C. Y.; Mayeda, M.; Wiesmann, C.; Sutherlin, D.; Wolf, B. B. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar-and N-blocked-boroPro inhibitors of FAP, DPP4 and POP Bioorg. Med. Chem. Lett. 2007, 17, 1438-1442
23. Tsai, T.; Yeh, T.; Chen, X.; Hsu, T.; Jao, Y.; Huang, C.; Song, J.; Huang, Y.; Chien, C.; Chiu, J.; Yen, S.; Tang, H.; Chao, Y.; Jiaang, W. Substituted 4-caboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein J. Med. Chem. 2010, 53, 6572-6583
24. Ryabtsova, O.; Jansen, K.; Van Goethem, S.; Joossens, J.; Cheng, J. D.; Lambeir, A.; De Meester, I.; Augustyns, K.; Van der Veken, P. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issues of FAP/prolyl oligopeptidase (PREP)-selectivity Bioorg. Med. Chem. Lett. 2012, 22, 3412-3417
25. Lee, K. N.; Jackson, K. W.; Christiansen, V. J.; Lee, C. S.; Chun, J. G.; McKee, P. A. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein Blood 2006, 107, 1397-1404
26. Tenorio-Laranga, J.; Venäläinen, J. I.; Männistö, P. T.; García-Horsman, J. A. Characterization of membrane-bound prolyl endopeptidase from brain FEBS J. 2008, 275, 4415-4427
27. Irazusta, J.; Larrinaga, G.; González-Maeso, J.; Gil, J.; Meana, J. J.; Casis, L. Distribution of prolyl endopeptidase activities in rat and human brain Neurochem. Int. 2002, 40, 337-345
28. Myöhänen, T. T.; Pyykkö, E.; Männistö, P. T.; Carpen, O. Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors J. Histochem. Cytochem. 2012, 60, 706-715
29. Turk, B. Targeting proteases: successes, failures and future prospects Nat. Rev. Drug Discovery 2006, 5, 785-799
30. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Drug Discovery 2011, 10, 307-317
31. Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future Med. Chem. 2010, 2, 949-964
32. Sanderson, P. E. Small, noncovalent serine protease inhibitors Med. Res. Rev. 1999, 19, 179-197
33. Bachovchin, D. A.; Cravatt, B. F. The pharmacological landscape and therapeutic potential of serine hydrolases Nat. Rev. Drug Discovery 2012, 11, 52-68
34. Edosada, C. Y.; Quan, C.; Tran, T.; Pham, V.; Wiesmann, C.; Fairbrother, W.; Wolf, B. B. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity FEBS Lett. 2006, 580, 1581-1586
35. Aggarwal, S.; Brennen, W. N.; Kole, T. P.; Schneider, E.; Topaloglu, O.; Yates, M.; Cotter, R. J.; Denmeade, S. R. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites Biochemistry 2008, 47, 1076-1086
36. Wolf, B. B.; Quan, C.; Tran, T.; Wiesmann, C.; Sutherlin, D. On the edge of validation-cancer protease fibroblast activation protein Mini-Rev. Med. Chem. 2008, 8, 719-727
37. Fülöp, V.; Böcskei, Z.; Polgár, L. Prolyl oligopeptidase; an unusual beta-propeller domain regulates proteolysis Cell 1998, 94, 161-170
38. Wang, X. M.; Yu, D. M. T.; McCaughan, W.; Gorrell, M. D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line Hepatology 2005, 42, 935-945
39. Sunwoo, J. B.; Chen, Z.; Dong, G.; Yeh, N.; Bancroft, C. C.; Sausville, E.; Adams, J.; Elliot, P.; Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin. Cancer Res. 2001, 7, 1419-1428
40. Coutts, S. J.; Kelly, T. A.; Snow, R. J.; Kennedy, C. A.; Barton, R. W.; Adams, J.; Krolikowski, D. A.; Freeman, D. M.; Campbell, S. J.; Ksiazek, J. F.; Bachovchin, W. W. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides J. Med. Chem. 1996, 39, 2087-2094
41. Milo, L. J.; Lai, J. H.; Wu, W.; Liu, Y.; Maw, H.; Li, Y.; Jin, Z.; Shu, Y.; Poplawski, S. E.; Wu, Y.; Sanford, D. G.; Sudmeier, J. L.; Bachovchin, W. W. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors J. Med. Chem. 2011, 54, 4365-4377
42. Poplawski, S. E.; Li, Y.; Shu, Y.; Zhang, M.; DiMare, M. T.; Sanford, D. G.; Lai, J. H.; Cheng, J. D.; Gorrell, M. D.; Bachovchin, W. W. Unpublished data.